Medline ® Abstract for Reference 56
of 'Nonarteritic ischemic optic neuropathy: Prognosis and treatment'
Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy.
Jonas JB, Spandau UH, Harder B, Sauder G
Graefes Arch Clin Exp Ophthalmol. 2007;245(5):749. Epub 2006 May 4.
PURPOSE: To report on the use of intravitreal triamcinolone acetonide as treatment for nonarteritic anterior ischemic optic neuropathy (NAION).
METHODS: The interventional clinical case series included three patients with acute NAION who received an intravitreal injection of about 20 mg triamcinolone acetonide.
RESULTS: At the end of follow-up at 3 months, 3.5 months and at 5 months after the injection, visual acuity had changed from 0.10 at baseline to 0.20 in the first patient, from 0.50 to 0.20 in the second patient, and from 0.16 to 0.20 in the third patient. One eye developed triamcinolone-induced ocular hypertension which was treated by topical antiglaucomatous medication.
CONCLUSIONS: The clinical courses of all three patients presented suggest that an intravitreal high-dosage injection of triamcinolone acetonide may not be markedly effective in increasing visualacuity after acute NAION.
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de